首页 > 最新文献

Archives of pathology & laboratory medicine最新文献

英文 中文
Pharmacogenomic Testing. 药物基因组学测试。
IF 3.2 Pub Date : 2025-11-22 DOI: 10.5858/arpa.2025-0179-CP
Yuan Ji, Lindsey Brunk, Betsy Bove, Karamatullah Danyal, Loralie J Langman, Nicole Mot, Pawel Mroz, Marvin Natowicz, Honey Reddi, Brian Shirts, Kristi Smock, Geoffrey D Wool, Bing Melody Zhang, Ann M Moyer

Context.—: Clinical laboratories are increasingly implementing pharmacogenomic (PGx) testing. Although PGx is similar to genetic testing for other indications, there are unique aspects that laboratories should consider.

Objective.—: To aid clinical laboratories that are implementing clinical PGx testing by describing characteristics of PGx test design and validation, as well as approaches to reporting. Resources that are useful for clinical laboratories performing PGx testing will be highlighted.

Design.—: The College of American Pathologists formed a workgroup composed of laboratorians with expertise in clinical PGx testing. The workgroup included representatives from the Association for Molecular Pathology and the American College of Medical Genetics and Genomics. The workgroup reviewed pertinent literature, as well as experience from proficiency testing and from members' laboratories.

Results.—: The workgroup recommends that laboratories implementing PGx consider the following concepts: testing platform, test design (ie, selection of pharmacogenes and variants/alleles), use of reference materials during test development and as controls during clinical runs, star allele and standard nomenclature systems, translations from genotype to predicted phenotype, and considerations for result reporting including making medication recommendations. The workgroup provides considerations when using report vendors, emphasizing the clinical laboratory's role and responsibility when implementing such reporting tools from vendors.

Conclusions.—: Clinical laboratories should be familiar with the fundamentals of PGx, ensure that PGx testing meets the applicable regulatory requirements for all aspects of the clinical laboratory testing process, and follow recommendations for standardization of nomenclature and reporting.

上下文。临床实验室越来越多地实施药物基因组学(PGx)检测。虽然PGx与其他适应症的基因检测相似,但实验室应考虑其独特的方面。-:通过描述PGx测试设计和验证的特征以及报告方法,帮助实施临床PGx测试的临床实验室。对临床实验室进行PGx检测有用的资源将被突出显示。美国病理学家学会成立了一个由具有临床PGx检测专业知识的实验室人员组成的工作组。该工作组包括来自分子病理学协会和美国医学遗传学和基因组学学院的代表。工作组审查了相关文献,以及来自能力测试和成员实验室的经验。-:工作组建议实施PGx的实验室考虑以下概念:测试平台、测试设计(即,药物基因和变异/等位基因的选择)、在测试开发期间使用参考材料和在临床运行期间作为对照、明星等位基因和标准命名系统、从基因型到预测表型的转换,以及对结果报告的考虑,包括提出药物建议。工作组提供了使用报告供应商时的考虑因素,强调了临床实验室在实施供应商提供的此类报告工具时的角色和责任。-:临床实验室应熟悉PGx的基础知识,确保PGx检测符合临床实验室检测流程各方面的适用法规要求,并遵循术语和报告标准化的建议。
{"title":"Pharmacogenomic Testing.","authors":"Yuan Ji, Lindsey Brunk, Betsy Bove, Karamatullah Danyal, Loralie J Langman, Nicole Mot, Pawel Mroz, Marvin Natowicz, Honey Reddi, Brian Shirts, Kristi Smock, Geoffrey D Wool, Bing Melody Zhang, Ann M Moyer","doi":"10.5858/arpa.2025-0179-CP","DOIUrl":"https://doi.org/10.5858/arpa.2025-0179-CP","url":null,"abstract":"<p><strong>Context.—: </strong>Clinical laboratories are increasingly implementing pharmacogenomic (PGx) testing. Although PGx is similar to genetic testing for other indications, there are unique aspects that laboratories should consider.</p><p><strong>Objective.—: </strong>To aid clinical laboratories that are implementing clinical PGx testing by describing characteristics of PGx test design and validation, as well as approaches to reporting. Resources that are useful for clinical laboratories performing PGx testing will be highlighted.</p><p><strong>Design.—: </strong>The College of American Pathologists formed a workgroup composed of laboratorians with expertise in clinical PGx testing. The workgroup included representatives from the Association for Molecular Pathology and the American College of Medical Genetics and Genomics. The workgroup reviewed pertinent literature, as well as experience from proficiency testing and from members' laboratories.</p><p><strong>Results.—: </strong>The workgroup recommends that laboratories implementing PGx consider the following concepts: testing platform, test design (ie, selection of pharmacogenes and variants/alleles), use of reference materials during test development and as controls during clinical runs, star allele and standard nomenclature systems, translations from genotype to predicted phenotype, and considerations for result reporting including making medication recommendations. The workgroup provides considerations when using report vendors, emphasizing the clinical laboratory's role and responsibility when implementing such reporting tools from vendors.</p><p><strong>Conclusions.—: </strong>Clinical laboratories should be familiar with the fundamentals of PGx, ensure that PGx testing meets the applicable regulatory requirements for all aspects of the clinical laboratory testing process, and follow recommendations for standardization of nomenclature and reporting.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Insights Into Succinate Dehydrogenase-Deficient Renal Cell Carcinoma. 琥珀酸脱氢酶缺陷肾细胞癌的新认识。
IF 3.2 Pub Date : 2025-11-21 DOI: 10.5858/arpa.2025-0233-OA
Junfeng Wu, Yilin Wang, Li Yang, Yingmei Wang, Peizhen Hu, Linni Fan, Yuqiao Xu

Context.—: Succinate dehydrogenase-deficient renal cell carcinoma (RCC) is a newly classified subtype of RCC in the World Health Organization classification of urinary and male genital tumours. However, systemic reports on this tumor are limited.

Objective.—: To give new insights into the clinicopathologic and molecular features of succinate dehydrogenase complex iron sulfur subunit B (SDHB)-deficient RCC.

Design.—: Data from 5 SDHB-deficient RCC patients diagnosed at our hospital between 2016 and 2022 were collected and studied through light microscopy, immunohistochemistry (IHC), ultrastructural analysis, and Sanger sequencing.

Results.—: The median age of patients was 34 years; 2 were male and 3 female. Grossly, the tumors were well defined, with an average diameter of 7 cm. Histologically, the cells were arranged in diverse patterns: solid, nested, glandular, or tubular with scattered cysts containing eosinophilic, wispy, or bubbly appearances. One patient's tumor exhibited an obvious papillary structure with focal aggregation of foam cells, and 3 tumors displayed focal micropapillary structures. Two patients presented with high-grade International Society of Urologic Pathology 3 nuclei. The tumor cells in all cases lacked SDHB expression by IHC stain. In addition, the average value of the combined positive score of programmed death ligand-1 (PD-L1, SP263) in all patients was 18. Electron microscopy revealed significant mitochondrial abnormalities. Genetic testing confirmed SDHB germline mutations in all tumors. One patient's tumor presented a novel, previously unreported mutation: c.697_700del in exon 7. Follow-up revealed metastasis in 1 patient, leading to mortality.

Conclusions.—: Our findings broaden the morphologic spectrum and highlight a new point mutation in the SDHB gene, providing a genetic change spectrum for this tumor entity.

上下文。-:琥珀酸脱氢酶缺陷肾细胞癌(RCC)是世界卫生组织泌尿和男性生殖器肿瘤分类中新近分类的RCC亚型。然而,关于该肿瘤的系统报道有限。-:为琥珀酸脱氢酶复合体铁硫亚基B (SDHB)缺陷rcc的临床病理和分子特征提供新的见解。-:收集2016年至2022年在我院诊断的5例sdhb缺陷RCC患者的数据,通过光镜、免疫组化(IHC)、超微结构分析和Sanger测序进行研究。-:患者年龄中位数为34岁;2名男性,3名女性。肉眼可见,肿瘤界限清晰,平均直径为7cm。组织学上,细胞排列多样:实心、巢状、腺状或管状,散在的囊肿含有嗜酸性、丝状或泡状外观。1例肿瘤表现为明显的乳头状结构伴局灶性泡沫细胞聚集,3例肿瘤表现为局灶性微乳头状结构。2例患者表现为国际泌尿病理学会3级核。免疫组化染色显示,所有病例的肿瘤细胞均缺乏SDHB的表达。此外,所有患者的程序性死亡配体-1 (PD-L1, SP263)联合阳性评分平均值为18。电镜显示明显的线粒体异常。基因检测证实在所有肿瘤中存在SDHB种系突变。一名患者的肿瘤出现了一种新的、以前未报道的突变:第7外显子的c.697_700del。随访发现1例患者发生转移,导致死亡。-:我们的发现拓宽了形态学谱,突出了SDHB基因的一个新的点突变,为该肿瘤实体提供了一个遗传变化谱。
{"title":"New Insights Into Succinate Dehydrogenase-Deficient Renal Cell Carcinoma.","authors":"Junfeng Wu, Yilin Wang, Li Yang, Yingmei Wang, Peizhen Hu, Linni Fan, Yuqiao Xu","doi":"10.5858/arpa.2025-0233-OA","DOIUrl":"https://doi.org/10.5858/arpa.2025-0233-OA","url":null,"abstract":"<p><strong>Context.—: </strong>Succinate dehydrogenase-deficient renal cell carcinoma (RCC) is a newly classified subtype of RCC in the World Health Organization classification of urinary and male genital tumours. However, systemic reports on this tumor are limited.</p><p><strong>Objective.—: </strong>To give new insights into the clinicopathologic and molecular features of succinate dehydrogenase complex iron sulfur subunit B (SDHB)-deficient RCC.</p><p><strong>Design.—: </strong>Data from 5 SDHB-deficient RCC patients diagnosed at our hospital between 2016 and 2022 were collected and studied through light microscopy, immunohistochemistry (IHC), ultrastructural analysis, and Sanger sequencing.</p><p><strong>Results.—: </strong>The median age of patients was 34 years; 2 were male and 3 female. Grossly, the tumors were well defined, with an average diameter of 7 cm. Histologically, the cells were arranged in diverse patterns: solid, nested, glandular, or tubular with scattered cysts containing eosinophilic, wispy, or bubbly appearances. One patient's tumor exhibited an obvious papillary structure with focal aggregation of foam cells, and 3 tumors displayed focal micropapillary structures. Two patients presented with high-grade International Society of Urologic Pathology 3 nuclei. The tumor cells in all cases lacked SDHB expression by IHC stain. In addition, the average value of the combined positive score of programmed death ligand-1 (PD-L1, SP263) in all patients was 18. Electron microscopy revealed significant mitochondrial abnormalities. Genetic testing confirmed SDHB germline mutations in all tumors. One patient's tumor presented a novel, previously unreported mutation: c.697_700del in exon 7. Follow-up revealed metastasis in 1 patient, leading to mortality.</p><p><strong>Conclusions.—: </strong>Our findings broaden the morphologic spectrum and highlight a new point mutation in the SDHB gene, providing a genetic change spectrum for this tumor entity.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Validation Study of an Expanded Description of Glandular (Acinar)/Tubule Formation for the Use of Nottingham Grading System for Invasive Breast Carcinomas Demonstrates Improvement in Concordance for Breast Pathologists and Trainees in Pathology. 一项对浸润性乳腺癌使用诺丁汉分级系统扩展描述腺(腺泡)/小管形成的验证研究表明,乳腺病理学家和病理学培训生的一致性得到改善。
IF 3.2 Pub Date : 2025-11-03 DOI: 10.5858/arpa.2025-0280-OA
Cansu Karakas, Rana A Aldrees, Anas Mohamed, Ian O Ellis, Susan A Fineberg, Marie-Helene Ngo, Stuart J Schnitt, Susan C Lester

Context.—: The Nottingham grading system, developed by Elston and Ellis, is the recommended method for grading invasive breast carcinoma. A previous study demonstrated the mean concordance for 35 breast pathologists in classifying 58 images as glandular (acinar)/tubule formation (G/TF) based on the World Health Organization definition was only 64%.

Objective.—: To determine if an expanded description of G/TF according to the original definition and current use of the Nottingham grading system would improve recognition of G/TF among breast pathologists and pathologists in training.

Design.—: Fifty-eight images with one structure circled were classified as G/TF or non-G/TF by Dr Ian Ellis. Images were sent as a PowerPoint (Microsoft) file to the breast pathologists who participated in the original study and to 21 trainees. Participants were asked to classify the structures based on the expanded description and were also provided with the 58 images from the first study with annotation.

Results.—: Among the participating 28 of the original 35 breast pathologists, the mean concordance increased from 64% (range, 40%-97%) to 94% (range, 86%-100%). Trainees had a mean concordance of 90% (range, 52%-100%).

Conclusions.—: The expanded description assisted in the recognition of G/TF for both breast pathologists and trainees. The most important impact on grading will likely be for carcinomas with complex cribriform patterns or micropapillary patterns with "inverted tubules." Participants endorsed that the expanded description of G/TF and the annotated images would be helpful reference material for pathologists.

上下文。-:由Elston和Ellis开发的诺丁汉分级系统是对浸润性乳腺癌进行分级的推荐方法。先前的一项研究表明,35名乳腺病理学家对58张基于世界卫生组织定义的腺(腺泡)/小管形成(G/TF)图像进行分类的平均一致性仅为64%。目的:确定根据原始定义和目前使用的诺丁汉分级系统对G/TF的扩展描述是否会提高乳腺病理学家和培训病理学家对G/TF的认识。-:伊恩·埃利斯博士将58张带有一个圈状结构的图像分类为G/TF或非G/TF。图像以PowerPoint (Microsoft)文件的形式发送给参与原始研究的乳腺病理学家和21名学员。参与者被要求根据扩展的描述对结构进行分类,并提供了第一项研究的58张带有注释的图像。-:原来35名乳腺病理学家中28名的平均一致性从64%(范围,40%-97%)增加到94%(范围,86%-100%)。受训者的平均一致性为90%(范围为52%-100%)。-:扩展的描述有助于乳腺病理学家和培训生对G/TF的识别。对分级最重要的影响可能是具有复杂筛状模式或具有“倒小管”的微乳头状模式的癌。与会者赞同G/TF的扩展描述和注释图像将是病理学家有用的参考材料。
{"title":"A Validation Study of an Expanded Description of Glandular (Acinar)/Tubule Formation for the Use of Nottingham Grading System for Invasive Breast Carcinomas Demonstrates Improvement in Concordance for Breast Pathologists and Trainees in Pathology.","authors":"Cansu Karakas, Rana A Aldrees, Anas Mohamed, Ian O Ellis, Susan A Fineberg, Marie-Helene Ngo, Stuart J Schnitt, Susan C Lester","doi":"10.5858/arpa.2025-0280-OA","DOIUrl":"https://doi.org/10.5858/arpa.2025-0280-OA","url":null,"abstract":"<p><strong>Context.—: </strong>The Nottingham grading system, developed by Elston and Ellis, is the recommended method for grading invasive breast carcinoma. A previous study demonstrated the mean concordance for 35 breast pathologists in classifying 58 images as glandular (acinar)/tubule formation (G/TF) based on the World Health Organization definition was only 64%.</p><p><strong>Objective.—: </strong>To determine if an expanded description of G/TF according to the original definition and current use of the Nottingham grading system would improve recognition of G/TF among breast pathologists and pathologists in training.</p><p><strong>Design.—: </strong>Fifty-eight images with one structure circled were classified as G/TF or non-G/TF by Dr Ian Ellis. Images were sent as a PowerPoint (Microsoft) file to the breast pathologists who participated in the original study and to 21 trainees. Participants were asked to classify the structures based on the expanded description and were also provided with the 58 images from the first study with annotation.</p><p><strong>Results.—: </strong>Among the participating 28 of the original 35 breast pathologists, the mean concordance increased from 64% (range, 40%-97%) to 94% (range, 86%-100%). Trainees had a mean concordance of 90% (range, 52%-100%).</p><p><strong>Conclusions.—: </strong>The expanded description assisted in the recognition of G/TF for both breast pathologists and trainees. The most important impact on grading will likely be for carcinomas with complex cribriform patterns or micropapillary patterns with \"inverted tubules.\" Participants endorsed that the expanded description of G/TF and the annotated images would be helpful reference material for pathologists.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of Human Papillomavirus Self-collection for Cervical Cancer Screening in Community Outreach Programs. 人乳头瘤病毒自我收集在社区外展项目中用于宫颈癌筛查的有效性。
IF 3.2 Pub Date : 2025-10-31 DOI: 10.5858/arpa.2025-0325-OA
Zhengchun Lu, Rabeka Ali, Rhiannon Gall, Erandi Velazquez-Miranda, Chengyun Tang, Marcela Riveros Angel, Vanderlene L Kung, Guang Fan

Context.—: On May 14, 2024, the US Food and Drug Administration (FDA) approved self-collected vaginal samples for human papillomavirus (HPV) testing, expanding cervical cancer screening access.

Objective.—: To evaluate the feasibility and acceptability of HPV self-collection through community outreach programs targeting underscreened populations in Oregon.

Design.—: From October 2024 to June 2025, women aged 25 to 65 years were recruited through local organizations. Following instruction by pathologists, participants completed self-collection by using Copan swabs, which were transferred to ThinPrep media for high-risk HPV testing using the Cobas 8800 system. Postcollection surveys assessed user experience.

Results.—: Among 156 participants (mean age, 47.1 years), 87 (55.8%) identified as Hispanic and 69 (44.2%) as non-Hispanic. Racial groups included Hispanic White (87; 55.8%), Asian (33; 21.1%), Black (16; 10.3%), non-Hispanic White (14; 9.0%), Pacific Islander (2; 1.3%), and nondisclosed (4; 2.5%). All tests were valid; 10 participants (6.4%) were HPV-positive, including 1 with HPV-18 and 9 with non-16/18 types. Follow-up cytology showed 1 case of atypical squamous cells of undetermined significance and 2 negative results; the remainder are pending follow-up. Of 129 survey respondents, 8 (6.2%) had received the HPV vaccine. Overall, 117 (90.7%) found the self-collection kit easy to use, 114 (88.4%) would recommend it, and 91 (70.6%) were likely to choose self-collection over clinician-collected samples for future testing. Common feedback included convenience, comfort, and privacy.

Conclusions.—: HPV self-collection is a practical, user-friendly, and accessible screening option. Pathologist-led outreach may help close screening gaps. This study represents the first academic center-led implementation of FDA-approved self-collection in US community settings.

上下文。-: 2024年5月14日,美国食品和药物管理局(FDA)批准自行采集阴道样本用于人类乳头瘤病毒(HPV)检测,扩大宫颈癌筛查的可及性。-:通过针对俄勒冈州筛查不足人群的社区外展项目,评估HPV自我采集的可行性和可接受性。-:从2024年10月到2025年6月,通过地方组织招募25至65岁的妇女。在病理学家的指导下,参与者通过使用Copan拭子完成自我收集,并将其转移到ThinPrep培养基上,使用Cobas 8800系统进行高危HPV检测。收集后的调查评估了用户体验。在156名参与者(平均年龄47.1岁)中,87名(55.8%)为西班牙裔,69名(44.2%)为非西班牙裔。种族群体包括西班牙裔白人(87人;55.8%)、亚洲人(33人;21.1%)、黑人(16人;10.3%)、非西班牙裔白人(14人;9.0%)、太平洋岛民(2人;1.3%)和非公开(4人;2.5%)。所有试验均有效;hpv阳性10例(6.4%),其中HPV-18型1例,非16/18型9例。随访细胞学检查显示1例意义不明的非典型鳞状细胞,2例阴性;其余的尚待后续处理。在129名受访者中,有8人(6.2%)接种了HPV疫苗。总体而言,117人(90.7%)认为自我采集试剂盒易于使用,114人(88.4%)推荐使用,91人(70.6%)可能会选择自我采集而不是临床采集的样本进行未来检测。常见的反馈包括方便、舒适和隐私。-: HPV自我收集是一种实用的,用户友好的,可访问的筛查选择。病理学家主导的外展可能有助于缩小筛查差距。这项研究代表了第一个由学术中心主导的fda批准的自我收集在美国社区环境中的实施。
{"title":"Effectiveness of Human Papillomavirus Self-collection for Cervical Cancer Screening in Community Outreach Programs.","authors":"Zhengchun Lu, Rabeka Ali, Rhiannon Gall, Erandi Velazquez-Miranda, Chengyun Tang, Marcela Riveros Angel, Vanderlene L Kung, Guang Fan","doi":"10.5858/arpa.2025-0325-OA","DOIUrl":"https://doi.org/10.5858/arpa.2025-0325-OA","url":null,"abstract":"<p><strong>Context.—: </strong>On May 14, 2024, the US Food and Drug Administration (FDA) approved self-collected vaginal samples for human papillomavirus (HPV) testing, expanding cervical cancer screening access.</p><p><strong>Objective.—: </strong>To evaluate the feasibility and acceptability of HPV self-collection through community outreach programs targeting underscreened populations in Oregon.</p><p><strong>Design.—: </strong>From October 2024 to June 2025, women aged 25 to 65 years were recruited through local organizations. Following instruction by pathologists, participants completed self-collection by using Copan swabs, which were transferred to ThinPrep media for high-risk HPV testing using the Cobas 8800 system. Postcollection surveys assessed user experience.</p><p><strong>Results.—: </strong>Among 156 participants (mean age, 47.1 years), 87 (55.8%) identified as Hispanic and 69 (44.2%) as non-Hispanic. Racial groups included Hispanic White (87; 55.8%), Asian (33; 21.1%), Black (16; 10.3%), non-Hispanic White (14; 9.0%), Pacific Islander (2; 1.3%), and nondisclosed (4; 2.5%). All tests were valid; 10 participants (6.4%) were HPV-positive, including 1 with HPV-18 and 9 with non-16/18 types. Follow-up cytology showed 1 case of atypical squamous cells of undetermined significance and 2 negative results; the remainder are pending follow-up. Of 129 survey respondents, 8 (6.2%) had received the HPV vaccine. Overall, 117 (90.7%) found the self-collection kit easy to use, 114 (88.4%) would recommend it, and 91 (70.6%) were likely to choose self-collection over clinician-collected samples for future testing. Common feedback included convenience, comfort, and privacy.</p><p><strong>Conclusions.—: </strong>HPV self-collection is a practical, user-friendly, and accessible screening option. Pathologist-led outreach may help close screening gaps. This study represents the first academic center-led implementation of FDA-approved self-collection in US community settings.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145411081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Novel Mindray BC-7800 and Sysmex XN-3000 Hematology Analyzers in Specimens With Platelet Interferences. 新型迈瑞BC-7800和Sysmex XN-3000血液学分析仪在血小板干扰标本中的评价
IF 3.2 Pub Date : 2025-10-31 DOI: 10.5858/arpa.2025-0206-OA
Chaicharoen Tantanate, Ladawan Khowawisetsut, Kasama Sukapirom, Kovit Pattanapanyasat

Context.—: Before adopting a new hematology analyzer in clinical laboratories, evaluating its platelet counting performance is critical.

Objectives.—: To assess the analytical performance of impedance (PLT-I), hybrid (PLT-H), and optical (PLT-O) platelet counts on the novel Mindray BC-7800 (BC-7800) and to compare platelet parameters obtained from the BC-7800 and Sysmex XN-3000 (XN-3000), including PLT-I, PLT-O, and PLT-F (optical fluorescent platelet count using oxazine dye), against the international reference method (IRM) in specimens with platelet interferences.

Design.—: Analytical parameters of the BC-7800, including limit of blank, linearity, reproducibility, and carryover, were evaluated. Interference testing included 126 specimens with red blood cell (RBC) microcytosis and 21 specimens from patients with blasts. Diagnostic performance against the IRM was assessed at platelet transfusion thresholds of 10 × 103/µL and 20 × 103/µL.

Results.—: The BC-7800 met acceptable criteria for most basic parameters, except within-run precision for PLT-I and PLT-H in some thrombocytopenic specimens. In RBC microcytosis, all methods showed strong correlations with the IRM, though PLT-I exhibited proportional bias. In leukemia specimens, PLT-O from the BC-7800 and PLT-F from the XN-3000 showed the strongest agreement with the IRM, while PLT-H and PLT-O from the XN-3000 exhibited systematic bias. Specificity and positive predictive value were excellent across all methods. Sensitivity, negative predictive value, and accuracy were highest for PLT-O from the BC-7800 and PLT-F.

Conclusions.—: The BC-7800 demonstrated reliable platelet analysis, particularly with PLT-O in thrombocytopenic and interference-prone specimens. PLT-H and optical fluorescent platelet methods showed strong reliability in specimens with RBC microcytosis, while PLT-O from the BC-7800 and PLT-F offered the highest accuracy for guiding platelet transfusion decisions.

上下文。在临床实验室采用一种新的血液分析仪之前,评估其血小板计数性能是至关重要的。-:评估新型迈瑞BC-7800 (BC-7800)的阻抗(PLT-I)、混合(PLT-H)和光学(PLT-O)血小板计数的分析性能,并将BC-7800和Sysmex XN-3000 (XN-3000)获得的血小板参数,包括PLT-I、PLT-O和PLT-F(使用草嗪染料的光学荧光血小板计数)与国际参考方法(IRM)在血小板干扰标本中的比较。-:对BC-7800的分析参数进行了评价,包括空白限、线性、重现性和携带性。干扰试验包括126例红细胞(RBC)小细胞增多症标本和21例原细胞患者标本。在血小板输注阈值为10 × 103/µL和20 × 103/µL时评估IRM的诊断性能。-: BC-7800除了在一些血小板减少标本中PLT-I和PLT-H的运行精度外,大多数基本参数都符合可接受的标准。在RBC小细胞增多症中,尽管PLT-I表现出比例偏差,但所有方法都显示与IRM有很强的相关性。在白血病标本中,BC-7800的PLT-O和XN-3000的PLT-F与IRM的一致性最强,而XN-3000的PLT-H和PLT-O则表现出系统偏差。所有方法的特异性和阳性预测值都很好。BC-7800的PLT-O和plt - f的敏感性、阴性预测值和准确性最高。BC-7800表现出可靠的血小板分析,特别是在血小板减少和易受干扰的标本中使用PLT-O。PLT-H和光学荧光血小板方法在RBC小细胞增多的标本中显示出很强的可靠性,而BC-7800的PLT-O和PLT-F在指导血小板输注决策方面提供了最高的准确性。
{"title":"Evaluation of the Novel Mindray BC-7800 and Sysmex XN-3000 Hematology Analyzers in Specimens With Platelet Interferences.","authors":"Chaicharoen Tantanate, Ladawan Khowawisetsut, Kasama Sukapirom, Kovit Pattanapanyasat","doi":"10.5858/arpa.2025-0206-OA","DOIUrl":"https://doi.org/10.5858/arpa.2025-0206-OA","url":null,"abstract":"<p><strong>Context.—: </strong>Before adopting a new hematology analyzer in clinical laboratories, evaluating its platelet counting performance is critical.</p><p><strong>Objectives.—: </strong>To assess the analytical performance of impedance (PLT-I), hybrid (PLT-H), and optical (PLT-O) platelet counts on the novel Mindray BC-7800 (BC-7800) and to compare platelet parameters obtained from the BC-7800 and Sysmex XN-3000 (XN-3000), including PLT-I, PLT-O, and PLT-F (optical fluorescent platelet count using oxazine dye), against the international reference method (IRM) in specimens with platelet interferences.</p><p><strong>Design.—: </strong>Analytical parameters of the BC-7800, including limit of blank, linearity, reproducibility, and carryover, were evaluated. Interference testing included 126 specimens with red blood cell (RBC) microcytosis and 21 specimens from patients with blasts. Diagnostic performance against the IRM was assessed at platelet transfusion thresholds of 10 × 103/µL and 20 × 103/µL.</p><p><strong>Results.—: </strong>The BC-7800 met acceptable criteria for most basic parameters, except within-run precision for PLT-I and PLT-H in some thrombocytopenic specimens. In RBC microcytosis, all methods showed strong correlations with the IRM, though PLT-I exhibited proportional bias. In leukemia specimens, PLT-O from the BC-7800 and PLT-F from the XN-3000 showed the strongest agreement with the IRM, while PLT-H and PLT-O from the XN-3000 exhibited systematic bias. Specificity and positive predictive value were excellent across all methods. Sensitivity, negative predictive value, and accuracy were highest for PLT-O from the BC-7800 and PLT-F.</p><p><strong>Conclusions.—: </strong>The BC-7800 demonstrated reliable platelet analysis, particularly with PLT-O in thrombocytopenic and interference-prone specimens. PLT-H and optical fluorescent platelet methods showed strong reliability in specimens with RBC microcytosis, while PLT-O from the BC-7800 and PLT-F offered the highest accuracy for guiding platelet transfusion decisions.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145423226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Success With Which the College of American Pathologists Practice Management Committee Provides Pathology Practice Management and Business Operation Intelligence. 美国病理医师学会执业管理委员会提供病理执业管理和商业运作情报的成功评价。
IF 3.2 Pub Date : 2025-10-31 DOI: 10.5858/arpa.2025-0217-CP
Diana Lin, Jacqueline Glanton, Mary O'Grady, Shania Faith Swain, David Novis

Context.—: Despite studies indicating its importance to pathology practice, there is a perception that pathologists are poorly trained in management and business operational (MBO) skills. The College of American Pathologists charges its Practice Management Committee (PMC) with providing MBO intelligence. PMC activities included the online course "Pathology Business Fundamentals" (PBF) and a series of roundtable webinars.

Objective.—: To determine the degree to which the PMC meets its charge of providing MBO education.

Design.—: We conducted evaluation surveys following the PBF course and roundtables. From these surveys we selected several outcome metrics to evaluate our objective.

Results.—: Six hundred fifty individuals attended the PBF course, 186 (29%) of whom completed course evaluation surveys. On a scale of 1 to 5 (5 = highest score), the mean aggregate score for "overall value" was 4.64. On a scale of 1 to 5 (5 = very likely), the mean aggregate score for our outcome metric, "intent to apply" was 4.54. Of 1539 individuals who had access to post-roundtable evaluation questionnaires, 378 (25%) completed evaluations; of these, 233 (62%) indicated that the PMC is their "primary source" for MBO. Of the 132 individuals who completed a second year-end roundtable evaluation survey, 98 (74%) agreed that the sessions were "one of the best sources available for support/guidance related to practice management."

Conclusions.—: To our knowledge, this is the first study evaluating MBO education effectiveness for postgraduate pathologists and laboratory professionals. Based on evaluation survey data, the PMC appears to achieve its mission of providing adequate laboratory and pathology MBO information.

上下文。-:尽管研究表明病理学对病理学实践的重要性,但人们认为病理学家在管理和业务操作(MBO)技能方面训练不足。美国病理学家学会要求其实践管理委员会(PMC)提供MBO情报。PMC活动包括在线课程“病理学商业基础”(PBF)和一系列圆桌网络研讨会。-:确定PMC在多大程度上满足其提供MBO教育的职责。-:我们在PBF课程和圆桌会议之后进行了评估调查。从这些调查中,我们选择了几个结果指标来评估我们的目标。650人参加了PBF课程,其中186人(29%)完成了课程评估调查。在1至5分(5为最高分)的评分范围内,“整体价值”的平均总分为4.64分。在1到5的范围内(5 =非常可能),我们的结果度量“应用意图”的平均总得分为4.54。1539名获得圆桌会议后评估问卷的个体中,378名(25%)完成了评估;其中,233人(62%)表示,PMC是其MBO的“主要来源”。在完成第二次年终圆桌评估调查的132个人中,98人(74%)同意会议是“与实践管理相关的支持/指导的最佳来源之一”。-:据我们所知,这是第一个评估研究生病理学家和实验室专业人员MBO教育效果的研究。基于评估调查数据,PMC似乎实现了提供足够的实验室和病理MBO信息的使命。
{"title":"Evaluation of the Success With Which the College of American Pathologists Practice Management Committee Provides Pathology Practice Management and Business Operation Intelligence.","authors":"Diana Lin, Jacqueline Glanton, Mary O'Grady, Shania Faith Swain, David Novis","doi":"10.5858/arpa.2025-0217-CP","DOIUrl":"https://doi.org/10.5858/arpa.2025-0217-CP","url":null,"abstract":"<p><strong>Context.—: </strong>Despite studies indicating its importance to pathology practice, there is a perception that pathologists are poorly trained in management and business operational (MBO) skills. The College of American Pathologists charges its Practice Management Committee (PMC) with providing MBO intelligence. PMC activities included the online course \"Pathology Business Fundamentals\" (PBF) and a series of roundtable webinars.</p><p><strong>Objective.—: </strong>To determine the degree to which the PMC meets its charge of providing MBO education.</p><p><strong>Design.—: </strong>We conducted evaluation surveys following the PBF course and roundtables. From these surveys we selected several outcome metrics to evaluate our objective.</p><p><strong>Results.—: </strong>Six hundred fifty individuals attended the PBF course, 186 (29%) of whom completed course evaluation surveys. On a scale of 1 to 5 (5 = highest score), the mean aggregate score for \"overall value\" was 4.64. On a scale of 1 to 5 (5 = very likely), the mean aggregate score for our outcome metric, \"intent to apply\" was 4.54. Of 1539 individuals who had access to post-roundtable evaluation questionnaires, 378 (25%) completed evaluations; of these, 233 (62%) indicated that the PMC is their \"primary source\" for MBO. Of the 132 individuals who completed a second year-end roundtable evaluation survey, 98 (74%) agreed that the sessions were \"one of the best sources available for support/guidance related to practice management.\"</p><p><strong>Conclusions.—: </strong>To our knowledge, this is the first study evaluating MBO education effectiveness for postgraduate pathologists and laboratory professionals. Based on evaluation survey data, the PMC appears to achieve its mission of providing adequate laboratory and pathology MBO information.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145423252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Success With Which the College of American Pathologists Practice Management Committee Provides Pathology Practice Management and Business Operation Intelligence. 美国病理医师学会执业管理委员会提供病理执业管理和商业运作情报的成功评价。
IF 3.2 Pub Date : 2025-10-31 DOI: 10.5858/arpa.2025-0217-CPR
Diana Lin, Jacqueline Glanton, Mary O'Grady, Shania Faith Swain, David Novis

Context.—: Despite studies indicating its importance to pathology practice, there is a perception that pathologists are poorly trained in management and business operational (MBO) skills. The College of American Pathologists charges its Practice Management Committee (PMC) with providing MBO intelligence. PMC activities included the online course "Pathology Business Fundamentals" (PBF) and a series of roundtable webinars.

Objective.—: To determine the degree to which the PMC meets its charge of providing MBO education.

Design.—: We conducted evaluation surveys following the PBF course and roundtables. From these surveys we selected several outcome metrics to evaluate our objective.

Results.—: Six hundred fifty individuals attended the PBF course, 186 (29%) of whom completed course evaluation surveys. On a scale of 1 to 5 (5 = highest score), the mean aggregate score for "overall value" was 4.64. On a scale of 1 to 5 (5 = very likely), the mean aggregate score for our outcome metric, "intent to apply" was 4.54. Of 1539 individuals who had access to post-roundtable evaluation questionnaires, 378 (25%) completed evaluations; of these, 233 (62%) indicated that the PMC is their "primary source" for MBO. Of the 132 individuals who completed a second year-end roundtable evaluation survey, 98 (74%) agreed that the sessions were "one of the best sources available for support/guidance related to practice management."

Conclusions.—: To our knowledge, this is the first study evaluating MBO education effectiveness for postgraduate pathologists and laboratory professionals. Based on evaluation survey data, the PMC appears to achieve its mission of providing adequate laboratory and pathology MBO information.

上下文。-:尽管研究表明病理学对病理学实践的重要性,但人们认为病理学家在管理和业务操作(MBO)技能方面训练不足。美国病理学家学会要求其实践管理委员会(PMC)提供MBO情报。PMC活动包括在线课程“病理学商业基础”(PBF)和一系列圆桌网络研讨会。-:确定PMC在多大程度上满足其提供MBO教育的职责。-:我们在PBF课程和圆桌会议之后进行了评估调查。从这些调查中,我们选择了几个结果指标来评估我们的目标。650人参加了PBF课程,其中186人(29%)完成了课程评估调查。在1至5分(5为最高分)的评分范围内,“整体价值”的平均总分为4.64分。在1到5的范围内(5 =非常可能),我们的结果度量“应用意图”的平均总得分为4.54。1539名获得圆桌会议后评估问卷的个体中,378名(25%)完成了评估;其中,233人(62%)表示,PMC是其MBO的“主要来源”。在完成第二次年终圆桌评估调查的132个人中,98人(74%)同意会议是“与实践管理相关的支持/指导的最佳来源之一”。-:据我们所知,这是第一个评估研究生病理学家和实验室专业人员MBO教育效果的研究。基于评估调查数据,PMC似乎实现了提供足够的实验室和病理MBO信息的使命。
{"title":"Evaluation of the Success With Which the College of American Pathologists Practice Management Committee Provides Pathology Practice Management and Business Operation Intelligence.","authors":"Diana Lin, Jacqueline Glanton, Mary O'Grady, Shania Faith Swain, David Novis","doi":"10.5858/arpa.2025-0217-CPR","DOIUrl":"https://doi.org/10.5858/arpa.2025-0217-CPR","url":null,"abstract":"<p><strong>Context.—: </strong>Despite studies indicating its importance to pathology practice, there is a perception that pathologists are poorly trained in management and business operational (MBO) skills. The College of American Pathologists charges its Practice Management Committee (PMC) with providing MBO intelligence. PMC activities included the online course \"Pathology Business Fundamentals\" (PBF) and a series of roundtable webinars.</p><p><strong>Objective.—: </strong>To determine the degree to which the PMC meets its charge of providing MBO education.</p><p><strong>Design.—: </strong>We conducted evaluation surveys following the PBF course and roundtables. From these surveys we selected several outcome metrics to evaluate our objective.</p><p><strong>Results.—: </strong>Six hundred fifty individuals attended the PBF course, 186 (29%) of whom completed course evaluation surveys. On a scale of 1 to 5 (5 = highest score), the mean aggregate score for \"overall value\" was 4.64. On a scale of 1 to 5 (5 = very likely), the mean aggregate score for our outcome metric, \"intent to apply\" was 4.54. Of 1539 individuals who had access to post-roundtable evaluation questionnaires, 378 (25%) completed evaluations; of these, 233 (62%) indicated that the PMC is their \"primary source\" for MBO. Of the 132 individuals who completed a second year-end roundtable evaluation survey, 98 (74%) agreed that the sessions were \"one of the best sources available for support/guidance related to practice management.\"</p><p><strong>Conclusions.—: </strong>To our knowledge, this is the first study evaluating MBO education effectiveness for postgraduate pathologists and laboratory professionals. Based on evaluation survey data, the PMC appears to achieve its mission of providing adequate laboratory and pathology MBO information.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145423593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue With EWSR1/FUS::NFATC2 Fusions. EWSR1/FUS::NFATC2融合的骨和软组织未分化小圆细胞肉瘤。
IF 3.2 Pub Date : 2025-10-31 DOI: 10.5858/arpa.2025-0202-RA
Lawrence J Jennings, Laura M Warmke, Michael Volek, Drew Duckett, Ritu Nayar, Seth M Pollack, Terrance D Peabody, Jonathan Samet, Borislav A Alexiev

Context.—: The latest WHO (World Health Organization) Classification of Bone and Soft Tissue Tumours (5th edition) has recently defined undifferentiated round cell sarcomas (URCSs) with EWSR1/FUS::NFATC2 (EWS RNA binding protein 1 or FUS RNA binding protein fused with nuclear factor of activated T cells 2) fusions. Given the rarity of this fusion, cytologic findings remain unreported, and information regarding clinical presentation, biological behavior, diagnostic markers, and molecular characteristics is scarce.

Objective.—: To provide a review of the clinicopathologic, molecular, and prognostic features of URCSs with EWSR1/FUS::NFATC2 fusions. Classic histopathologic findings, uncommon variations, and diagnostic pitfalls are addressed, along with the utility of recently developed immunohistochemical and molecular markers.

Data sources.—: Bringing together our institutional expertise and a thorough evaluation of the literature, this review captures key findings and trends through an extensive PubMed search. By integrating our own practical insights with evidence-based data, we offer a well-rounded perspective that sheds light on both foundational concepts and new advancements in the field.

Conclusions.—: This review underscores the importance of integrating clinicopathologic features and immunohistochemical results with EWSR1/FUS testing to effectively identify sarcomas with rare gene fusions via next-generation sequencing, which carry prognostic significance. Additionally, URCS-harboring EWSR/FUS::NFATC2 fusions exhibit notable differences from Ewing sarcoma and other URCSs, including a limited response to neoadjuvant chemotherapy; unique morphologic characteristics; and distinct genomic, transcriptomic, and epigenetic (methylation) profiles. Given the potential differences in biological behavior, accurate subclassification of EWSR1/FUS fusion variants is essential.

上下文。最新的WHO(世界卫生组织)骨和软组织肿瘤分类(第5版)最近将未分化圆细胞肉瘤(URCSs)定义为EWSR1/FUS::NFATC2 (EWS RNA结合蛋白1或FUS RNA结合蛋白与活化T细胞核因子融合2)融合物。鉴于这种融合的罕见性,细胞学结果尚未报道,有关临床表现、生物学行为、诊断标志物和分子特征的信息也很少。目的:综述EWSR1/FUS::NFATC2合并urcs的临床病理、分子和预后特征。经典的组织病理学发现,不常见的变异,和诊断陷阱,以及最近开发的免疫组织化学和分子标记的效用。数据源。-:结合我们的机构专业知识和对文献的全面评估,本综述通过广泛的PubMed搜索捕获了关键发现和趋势。通过将我们自己的实践见解与基于证据的数据相结合,我们提供了一个全面的视角,阐明了该领域的基本概念和新进展。-:本综述强调了将临床病理特征和免疫组织化学结果与EWSR1/FUS检测结合起来,通过下一代测序有效识别罕见基因融合肉瘤的重要性,这具有预后意义。此外,含有urcs的EWSR/FUS::NFATC2融合体与尤因肉瘤和其他urcs表现出显著差异,包括对新辅助化疗的有限反应;独特的形态特征;以及不同的基因组、转录组和表观遗传(甲基化)谱。考虑到生物学行为的潜在差异,对EWSR1/FUS融合变异体进行准确的亚分类至关重要。
{"title":"Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue With EWSR1/FUS::NFATC2 Fusions.","authors":"Lawrence J Jennings, Laura M Warmke, Michael Volek, Drew Duckett, Ritu Nayar, Seth M Pollack, Terrance D Peabody, Jonathan Samet, Borislav A Alexiev","doi":"10.5858/arpa.2025-0202-RA","DOIUrl":"https://doi.org/10.5858/arpa.2025-0202-RA","url":null,"abstract":"<p><strong>Context.—: </strong>The latest WHO (World Health Organization) Classification of Bone and Soft Tissue Tumours (5th edition) has recently defined undifferentiated round cell sarcomas (URCSs) with EWSR1/FUS::NFATC2 (EWS RNA binding protein 1 or FUS RNA binding protein fused with nuclear factor of activated T cells 2) fusions. Given the rarity of this fusion, cytologic findings remain unreported, and information regarding clinical presentation, biological behavior, diagnostic markers, and molecular characteristics is scarce.</p><p><strong>Objective.—: </strong>To provide a review of the clinicopathologic, molecular, and prognostic features of URCSs with EWSR1/FUS::NFATC2 fusions. Classic histopathologic findings, uncommon variations, and diagnostic pitfalls are addressed, along with the utility of recently developed immunohistochemical and molecular markers.</p><p><strong>Data sources.—: </strong>Bringing together our institutional expertise and a thorough evaluation of the literature, this review captures key findings and trends through an extensive PubMed search. By integrating our own practical insights with evidence-based data, we offer a well-rounded perspective that sheds light on both foundational concepts and new advancements in the field.</p><p><strong>Conclusions.—: </strong>This review underscores the importance of integrating clinicopathologic features and immunohistochemical results with EWSR1/FUS testing to effectively identify sarcomas with rare gene fusions via next-generation sequencing, which carry prognostic significance. Additionally, URCS-harboring EWSR/FUS::NFATC2 fusions exhibit notable differences from Ewing sarcoma and other URCSs, including a limited response to neoadjuvant chemotherapy; unique morphologic characteristics; and distinct genomic, transcriptomic, and epigenetic (methylation) profiles. Given the potential differences in biological behavior, accurate subclassification of EWSR1/FUS fusion variants is essential.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standardized Reporting of Core Needle Biopsy Tortuosity. 核心穿刺活检扭曲的标准化报告。
IF 3.2 Pub Date : 2025-10-20 DOI: 10.5858/arpa.2025-0028-OA
Jackson Jacobs, Dan Wiener, Tilak Pathak, Xavier Farré, Tuomas Mirtti, Andrew Janowczyk

Context.—: Core needle biopsies (CNBs) are among the most common biopsy procedures, yielding long, thin deformation-prone cores. Core deformation results in both distorted histologic features and tortuosity (ie, deviation from the ideal straight path) along the length of the core. Tortuosity creates challenges in slide preparation and downstream pathologist assessment (eg, absent diagnostically relevant tissue after sectioning), indicating a clinical need for its minimization. Despite this need, there is no standard protocol for reporting CNB tortuosity.

Objectives.—: To (1) establish an actionable protocol for scoring CNB tortuosity, (2) build BiopTort, a software tool assigning CNB images interpretable, tiered scores consistent with the protocol, and (3) investigate our protocol and BiopTort's impact on interpathologist concordance and scoring time.

Design.—: Using a held-out CNB data set (N = 167), 3 pathologists assessed tortuosity in 3 sequential stages: (1) Baseline: a 3-tier scale based on prior experience, (2) Protocol: rescored with our 4-tier Tortuosity Scoring Protocol, (3) BiopTort-Aided: rescored with the protocol alongside BiopTort. Interrater concordance for each stage, using the Fleiss κ, was recorded.

Results.—: Fleiss κ was 0.19, 0.40, and 0.63, and average time per slide was 8.0, 24.2, and 13.3 seconds for stages 1 to 3, respectively. BiopTort was statistically noninferior to human interrater pairwise concordance.

Conclusions.—: These results suggest our protocol lessens interpathologist variability, with BiopTort further reducing variability and scoring protocol employment time cost. When deployed in CNB quality control workflows, our computer-aided protocol appears well situated to facilitate standardized, efficient, and actionable reporting of CNB tortuosity. BiopTort is open-source (http://bioptort.com).

上下文。-:岩心穿刺活检(CNBs)是最常见的活检方法之一,产生的岩心又长又细,容易变形。岩心变形导致组织学特征的扭曲和沿岩心长度的扭曲(即偏离理想的直线路径)。扭曲给载玻片制备和下游病理学评估带来了挑战(例如,切片后缺少诊断相关组织),这表明临床需要将其最小化。尽管有这种需要,但没有报告CNB扭曲的标准协议。-:(1)建立一个可操作的CNB扭曲评分方案,(2)构建BiopTort,一个软件工具,为CNB图像分配可解释的、与方案一致的分层评分,以及(3)调查我们的方案和BiopTort对病理学家间一致性和评分时间的影响。-:使用CNB数据集(N = 167), 3名病理学家在3个连续阶段评估扭曲度:(1)基线:基于先前经验的3层量表,(2)方案:使用我们的4层扭曲度评分方案进行恢复,(3)生物侵权辅助:使用生物侵权方案进行恢复。使用Fleiss κ记录每个阶段的互译者一致性。-: Fleiss κ分别为0.19、0.40和0.63,第1 ~ 3阶段的平均每张幻灯片时间分别为8.0、24.2和13.3秒。生物侵权在统计学上不逊于人类相互配对一致性。这些结果表明,我们的方案减少了病理学家之间的可变性,而BiopTort进一步减少了可变性,并对方案的使用时间成本进行了评分。当在CNB质量控制工作流程中部署时,我们的计算机辅助协议似乎能够很好地促进CNB扭曲的标准化,高效和可操作的报告。BiopTort是开源的(http://bioptort.com)。
{"title":"Standardized Reporting of Core Needle Biopsy Tortuosity.","authors":"Jackson Jacobs, Dan Wiener, Tilak Pathak, Xavier Farré, Tuomas Mirtti, Andrew Janowczyk","doi":"10.5858/arpa.2025-0028-OA","DOIUrl":"https://doi.org/10.5858/arpa.2025-0028-OA","url":null,"abstract":"<p><strong>Context.—: </strong>Core needle biopsies (CNBs) are among the most common biopsy procedures, yielding long, thin deformation-prone cores. Core deformation results in both distorted histologic features and tortuosity (ie, deviation from the ideal straight path) along the length of the core. Tortuosity creates challenges in slide preparation and downstream pathologist assessment (eg, absent diagnostically relevant tissue after sectioning), indicating a clinical need for its minimization. Despite this need, there is no standard protocol for reporting CNB tortuosity.</p><p><strong>Objectives.—: </strong>To (1) establish an actionable protocol for scoring CNB tortuosity, (2) build BiopTort, a software tool assigning CNB images interpretable, tiered scores consistent with the protocol, and (3) investigate our protocol and BiopTort's impact on interpathologist concordance and scoring time.</p><p><strong>Design.—: </strong>Using a held-out CNB data set (N = 167), 3 pathologists assessed tortuosity in 3 sequential stages: (1) Baseline: a 3-tier scale based on prior experience, (2) Protocol: rescored with our 4-tier Tortuosity Scoring Protocol, (3) BiopTort-Aided: rescored with the protocol alongside BiopTort. Interrater concordance for each stage, using the Fleiss κ, was recorded.</p><p><strong>Results.—: </strong>Fleiss κ was 0.19, 0.40, and 0.63, and average time per slide was 8.0, 24.2, and 13.3 seconds for stages 1 to 3, respectively. BiopTort was statistically noninferior to human interrater pairwise concordance.</p><p><strong>Conclusions.—: </strong>These results suggest our protocol lessens interpathologist variability, with BiopTort further reducing variability and scoring protocol employment time cost. When deployed in CNB quality control workflows, our computer-aided protocol appears well situated to facilitate standardized, efficient, and actionable reporting of CNB tortuosity. BiopTort is open-source (http://bioptort.com).</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathologic Analysis of Patients With Adipose Tissue on Endometrial Biopsies. 子宫内膜活检中脂肪组织的临床病理分析。
IF 3.2 Pub Date : 2025-10-16 DOI: 10.5858/arpa.2025-0321-OA
Hisham F Bahmad, Sibel Gultekin, Andre Pinto

Context.—: The identification of adipose tissue in endometrial biopsy or curettage specimens is an important yet rare histologic finding that may suggest uterine perforation, warranting careful pathologic evaluation to distinguish it from histologic mimickers.

Objective.—: To assess the presence of adipose tissue in endometrial samples and evaluate its diagnostic challenges and clinical implications.

Design.—: A retrospective cohort study was performed on cases from an 8-year period in which adipose tissue was identified in endometrial biopsy or curettage specimens. Hematoxylin-eosin-stained sections were reviewed, and relevant clinical data, including postoperative outcomes, were analyzed.

Results.—: Twenty-three patients were included (mean age ± standard deviation, 60.6 ± 13.3 years); 18 of 23 patients (78.3%) underwent curettage. Endometrial polyp was the most common concurrent diagnosis (8 of 23; 34.8%). Uterine perforation was clinically identified intraoperatively in 6 cases (6 of 23; 26.1%), all managed without complications. Most samples (16 of 23; 69.6%) contained a small amount of adipose tissue (1%-25%). Common risk factors included fibroids (5 of 23; 21.74%); cervical stenosis, polyps, intrauterine synechiae (4 of 23; 17.39% each); and history of prior cesarean delivery (10 of 23; 43.48%). The mean interval to notify clinicians of the adipose finding was 2.79 ± 1.65 days. One patient developed a postoperative abscess, successfully treated with antibiotics. No significant associations were found between risk factors or adipose proportion and intraoperative detection or postoperative complications (all P ≥ .05).

Conclusions.—: While adipose tissue in endometrial specimens may indicate uterine perforation, it was not associated with significant adverse outcomes in this cohort. Pathologists must remain vigilant, as benign mimics such as pseudolipomatosis or lipomatous tumors should be excluded during evaluation.

上下文。-:子宫内膜活检或刮除标本中脂肪组织的发现是一个重要但罕见的组织学发现,可能提示子宫穿孔,需要仔细的病理评估,以区分其与组织学上的模仿。目的:评估子宫内膜样本中脂肪组织的存在,并评估其诊断挑战和临床意义。-:一项回顾性队列研究对8年期间子宫内膜活检或刮除标本中发现脂肪组织的病例进行了研究。复习苏木精-伊红染色切片,并分析相关临床资料,包括术后结果。-:纳入23例患者(平均年龄±标准差,60.6±13.3岁);23例患者中有18例(78.3%)行刮除术。子宫内膜息肉是最常见的并发诊断(8 / 23;34.8%)。术中发现子宫穿孔6例(23例中6例,26.1%),均无并发症。大多数样本(23个样本中的16个,占69.6%)含有少量脂肪组织(1%-25%)。常见的危险因素包括肌瘤(5 / 23,21.74%);宫颈狭窄、息肉、宫内粘连(23例中4例,各占17.39%);既往有剖宫产史(10 / 23,43.48%)。向临床医生通报脂肪发现的平均间隔时间为2.79±1.65天。一名患者术后出现脓肿,用抗生素成功治疗。危险因素或脂肪比例与术中检测或术后并发症无显著相关性(均P≥0.05)。-:虽然子宫内膜标本中的脂肪组织可能表明子宫穿孔,但在本队列中,它与显著的不良结局无关。病理学家必须保持警惕,因为在评估过程中应排除良性模拟,如假性脂肪瘤病或脂肪瘤性肿瘤。
{"title":"Clinicopathologic Analysis of Patients With Adipose Tissue on Endometrial Biopsies.","authors":"Hisham F Bahmad, Sibel Gultekin, Andre Pinto","doi":"10.5858/arpa.2025-0321-OA","DOIUrl":"https://doi.org/10.5858/arpa.2025-0321-OA","url":null,"abstract":"<p><strong>Context.—: </strong>The identification of adipose tissue in endometrial biopsy or curettage specimens is an important yet rare histologic finding that may suggest uterine perforation, warranting careful pathologic evaluation to distinguish it from histologic mimickers.</p><p><strong>Objective.—: </strong>To assess the presence of adipose tissue in endometrial samples and evaluate its diagnostic challenges and clinical implications.</p><p><strong>Design.—: </strong>A retrospective cohort study was performed on cases from an 8-year period in which adipose tissue was identified in endometrial biopsy or curettage specimens. Hematoxylin-eosin-stained sections were reviewed, and relevant clinical data, including postoperative outcomes, were analyzed.</p><p><strong>Results.—: </strong>Twenty-three patients were included (mean age ± standard deviation, 60.6 ± 13.3 years); 18 of 23 patients (78.3%) underwent curettage. Endometrial polyp was the most common concurrent diagnosis (8 of 23; 34.8%). Uterine perforation was clinically identified intraoperatively in 6 cases (6 of 23; 26.1%), all managed without complications. Most samples (16 of 23; 69.6%) contained a small amount of adipose tissue (1%-25%). Common risk factors included fibroids (5 of 23; 21.74%); cervical stenosis, polyps, intrauterine synechiae (4 of 23; 17.39% each); and history of prior cesarean delivery (10 of 23; 43.48%). The mean interval to notify clinicians of the adipose finding was 2.79 ± 1.65 days. One patient developed a postoperative abscess, successfully treated with antibiotics. No significant associations were found between risk factors or adipose proportion and intraoperative detection or postoperative complications (all P ≥ .05).</p><p><strong>Conclusions.—: </strong>While adipose tissue in endometrial specimens may indicate uterine perforation, it was not associated with significant adverse outcomes in this cohort. Pathologists must remain vigilant, as benign mimics such as pseudolipomatosis or lipomatous tumors should be excluded during evaluation.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145310241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Archives of pathology & laboratory medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1